May 13 (Reuters) - Reneo Pharmaceuticals Inc ( RPHM ):

* RENEO PHARMACEUTICALS AND ONKURE ANNOUNCE PROPOSED MERGER

* RENEO PHARMACEUTICALS INC ( RPHM ) - MERGER TO CREATE A

NASDAQ-LISTED,

CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY

* RENEO PHARMACEUTICALS INC ( RPHM ) - MERGED COMPANY TO BE NAMED

ONKURE

THERAPEUTICS

* RENEO PHARMACEUTICALS ( RPHM ): COMBINED CO EXPECTED TO OPERATE

UNDER

NAME ONKURE THERAPEUTICS, INC., TRADE ON NASDAQ GLOBAL MARKET

UNDER TICKER SYMBOL "OKUR"

* RENEO PHARMACEUTICALS INC ( RPHM ) - MERGER AND PIPE FINANCING

EXPECTED

TO CLOSE IN 2024

* RENEO PHARMACEUTICALS ( RPHM ): PRE-MERGER RENEO STOCKHOLDERS TO

OWN

ABOUT 31% OF COMBINED CO, PRE-MERGER ONKURE STOCKHOLDERS TO OWN

ABOUT 69% OF COMBINED CO

* RENEO PHARMACEUTICALS ( RPHM )- ENTERED INTO SUBSCRIPTION AGREEMENT

FOR

$65 MILLION PRIVATE INVESTMENT IN PUBLIC EQUITY (PIPE) FINANCING

* RENEO PHARMACEUTICALS INC ( RPHM ) - COMBINED COMPANY WILL BE LED

BY

NICHOLAS SACCOMANO, PRESIDENT & CEO OF ONKURE

* RENEO PHARMACEUTICALS INC ( RPHM ) - MERGER AGREEMENT PROVIDES THAT

BOARD

OF DIRECTORS OF COMBINED COMPANY WILL BE COMPOSED OF EIGHT

MEMBERS

* RENEO PHARMACEUTICALS INC ( RPHM ) - COMBINED CO IS EXPECTED TO

HAVE

APPROXIMATELY $120 MILLION OF CASH, CASH EQUIVALENTS, AND

SHORT-TERM INVESTMENTS AT CLOSING

Source text for Eikon:

Further company coverage: